ARGX vs. INCY: argenx vs. Incyte Stock Comparison
How do argenx (ARGX) and Incyte (INCY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
argenx (ARGX) and Incyte (INCY) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Incyte (INCY) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ARGX | INCY |
|---|---|---|
| Name | argenx SE American Depositary Receipt | Incyte Corp. |
| Country/Region | Netherlands | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 58.31 billion USD | 24.39 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 18, 2017 | November 4, 1993 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ARGX | INCY |
|---|---|---|
| Total Return (1Y) | 11.91% | 14.06% |
| Total Return (3Y, Annualized) | 25.68% | 32.03% |
| Total Return (5Y, Annualized) | 24.22% | 12.69% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ARGX | INCY |
|---|---|---|
| Volatility (1Y, Annualized) | 37.87% | 33.19% |
| Beta (5Y) | 0.45 | 0.78 |
| Max Drawdown (5Y) | -38.20% | -40.50% |
| Avg. Volume (3M) | 359.84K | 1.58M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ARGX | INCY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 0.29 |
| Sortino Ratio (1Y) | 0.31 | 0.46 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Incyte (INCY) earns 7.84% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ARGX
- --
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.84%
- Max
- 109.18%
- INCY
- 7.84%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
argenx (ARGX) at 31.73% keeps the most of each sales dollar — above its industry’s net margin range — and Incyte (INCY) at 6.71% also retains a top-quartile share.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.73%
- ARGX
- 31.73%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.71%
- Max
- 18.05%
- INCY
- 6.71%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both argenx (ARGX) at 36.27% and Incyte (INCY) at 33.72% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.27%
- Max
- 83.12%
- ARGX
- 36.27%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.72%
- Max
- 83.12%
- INCY
- 33.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ARGX | INCY |
|---|---|---|
| ROE (TTM) | -- | 7.84% |
| ROA (TTM) | -- | 17.78% |
| Net Margin (TTM) | 31.73% | 6.71% |
| Operating Margin (TTM) | 36.27% | 33.72% |
| Gross Margin (TTM) | 59.84% | 56.02% |
Growth
Revenue Growth
argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Incyte (INCY) at 21.22% is closer to the peer norm — faster top-line expansion for ARGX.
EPS Growth
Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than argenx (ARGX) at 53.13%, which is closer to a typical peer reading.
Growth Metrics
| Metric | ARGX | INCY |
|---|---|---|
| Revenue Growth (YoY) | 89.64% | 21.22% |
| Revenue Growth (3Y CAGR) | 116.25% | 14.84% |
| EPS Growth (YoY) | 53.13% | 4,173.33% |
| EPS Growth (3Y CAGR) | -- | 61.56% |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Incyte (INCY) shows current ratio of 3.84 against its industry benchmark, while argenx (ARGX) has no reading this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ARGX
- --
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.84
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INCY
- 3.84
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both argenx (ARGX) at 0.01 and Incyte (INCY) at 0.01 keep leverage in the lower quartile of their industries, with less balance-sheet debt relative to equity than most peers.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- ARGX
- 0.01
- Min
- 0.00
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- INCY
- 0.01
- Min
- 0.00
Financial Strength Metrics
| Metric | ARGX | INCY |
|---|---|---|
| Current Ratio (MRQ) | -- | 3.84 |
| Debt / Equity (MRQ) | 0.01 | 0.01 |
| Net Debt / EBITDA | -2.70 | -1.88 |
Dividends
Dividend Yield (TTM)
Neither argenx (ARGX) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither argenx (ARGX) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ARGX | INCY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
argenx (ARGX) at 32.12 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.12
- Max
- 85.34
- Q3
- 43.46
- ARGX
- 32.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.05
- Max
- 85.34
- INCY
- 61.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both argenx (ARGX) at 9.86 and Incyte (INCY) at 4.06 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.86
- Max
- 58.18
- Q3
- 25.77
- ARGX
- 9.86
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.06
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- INCY
- 4.06
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Incyte (INCY) at 4.33 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
172.23
- ARGX
- 172.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.33
- Max
- 13.53
- Q3
- 6.54
- INCY
- 4.33
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ARGX | INCY |
|---|---|---|
| P/E Ratio (TTM) | 32.12 | 61.05 |
| P/S Ratio (TTM) | 9.86 | 4.06 |
| P/B Ratio (MRQ) | 172.23 | 4.33 |
| Free Cash Flow Yield (TTM) | -- | 5.28% |